Prostate cancer incidence trends in Spain before and during the prostate-specific antigen era: impact on mortality

被引:35
|
作者
Larranaga, N. [1 ]
Galceran, J. [2 ]
Ardanaz, E. [3 ]
Franch, P. [4 ]
Navarro, C. [5 ]
Sanchez, M. J. [6 ]
Pastor-Barriuso, R. [7 ]
机构
[1] Basque Country Reg Author, Publ Hlth Dept Gipuzkoa, Basque Country Canc Registry, San Sebastian, Spain
[2] Pere Virgili Hlth Res Inst, Fdn Soc Canc Res & Prevent, Tarragona Canc Registry, Reus, Spain
[3] Navarre Publ Hlth Inst, Navarre Canc Registry, Pamplona, Spain
[4] Directorate Gen Publ Hlth & Participat, Dept Epidemiol, Mallorca Canc Registry, Palma De Mallorca, Spain
[5] Hlth Author, Dept Epidemiol, Murcia Canc Registry, Murcia, Spain
[6] Andalusian Sch Publ Hlth, Granada Canc Registry, Granada, Spain
[7] Carlos III Inst Hlth, Natl Ctr Epidemiol, Madrid, Spain
关键词
incidence; mortality; prostate neoplasms; Spain; PSA; trends; INTERPRETING TRENDS; SURVEILLANCE SERIES; RISING INCIDENCE; RISK; OVERDIAGNOSIS; SURVIVAL; DECREASE; EPIDEMIOLOGY; DIAGNOSIS; AUSTRIA;
D O I
10.1093/annonc/mdq087
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Materials and methods: The time trend in invasive prostate cancer incidence from 1975 to 2004 was studied by combining data from 13 Spanish population-based cancer registries. Change-point Poisson regression models were fitted for all men and for two age groups (45-64 and 65+ years). Age-period-cohort models were used to study cohort and period effects. In addition, we studied the time trend in prostate cancer mortality in Spain for the period 1980-2007. Results: Incidence increased annually by 1.3% from 1975 to 1990 and by 7.3% thereafter. Until 1990, the percentage increase was low and indeed similar for both age groups. While the subsequent increase in the two age groups was greater, this was particularly marked among the youngest men, with a decrease being observed in age groups > 85 years in the last quinquennium. Mortality increased by an annual figure of 0.7% until 1998, after which it decreased by 3.6% per annum until 2007. Conclusions: Despite the dramatic rise in incidence from 1990 onwards, mainly due to opportunistic screening, prostate cancer mortality was only observed to decline slowly from 1998. If prostate-specific antigen screening remains at a similar level in Spain, overdiagnosis may well become an important chronic side-effect and health problem.
引用
收藏
页码:iii83 / iii89
页数:7
相关论文
共 50 条
  • [1] Prostate cancer in Austria: impact of prostate-specific antigen test on incidence and mortality
    Vutuc, C
    Waldhoer, T
    Madersbacher, S
    Micksche, M
    Haidinger, G
    EUROPEAN JOURNAL OF CANCER PREVENTION, 2001, 10 (05) : 425 - 428
  • [2] Differences in Prostate Cancer Incidence and Mortality in Lower Saxony (Germany) and Groningen Province (Netherlands): Potential Impact of Prostate-Specific Antigen Testing
    Kappen, Sanny
    de Bock, Geertruida H.
    Sirri, Eunice
    Vohmann, Claudia
    Kieschke, Joachim
    Winter, Alexander
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [3] Prostate cancer incidence rates, trends, and treatment related to prostate-specific antigen screening recommendations in the United States
    Merrill, Ray M.
    CANCER EPIDEMIOLOGY, 2024, 93
  • [4] Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen
    Vickers, Andrew J.
    Sjoberg, Daniel D.
    Ulmert, David
    Vertosick, Emily
    Roobol, Monique J.
    Thompson, Ian
    Heijnsdijk, Eveline A. M.
    De Koning, Harry
    Atoria-Swartz, Coral
    Scardino, Peter T.
    Lilja, Hans
    BMC MEDICINE, 2014, 12
  • [5] Prostate-Specific Antigen and Long-Term Prediction of Prostate Cancer Incidence and Mortality in the General Population
    Orsted, David D.
    Nordestgaard, Borge G.
    Jensen, Gorm B.
    Schnohr, Peter
    Bojesen, Stig E.
    EUROPEAN UROLOGY, 2012, 61 (05) : 865 - 874
  • [6] Trends in mortality rates in patients with prostate cancer during the era of prostate specific antigen screening
    Merrill, RM
    Stephenson, RA
    JOURNAL OF UROLOGY, 2000, 163 (02) : 503 - 510
  • [7] Managing Localized Prostate Cancer in the Era of Prostate-Specific Antigen Screening
    Brooks, James D.
    CANCER, 2013, 119 (22) : 3906 - 3909
  • [8] Trends in incidence and mortality rates for prostate cancer before and after prostate-specific antigen introduction. A registry-based study in southeastern Netherlands, 1971-1995
    Post, PN
    Kil, PJM
    Crommelin, MA
    Schapers, RFM
    Coebergh, JWW
    EUROPEAN JOURNAL OF CANCER, 1998, 34 (05) : 705 - 709
  • [9] Prostate-specific antigen testing across the spectrum of prostate cancer
    Haythorn, Mark R.
    Ablin, Richard J.
    BIOMARKERS IN MEDICINE, 2011, 5 (04) : 515 - 526
  • [10] Can Prostate-Specific Antigen Kinetics before Prostate Biopsy Predict the Malignant Potential of Prostate Cancer?
    Kim, Sang Jin
    Jeong, Tae Yoong
    Yoo, Dae Seon
    Park, Jinsung
    Cho, Seok
    Kang, Seok Ho
    Lee, Sang Hyub
    Jeon, Seung Hyun
    Lee, Tchun Yong
    Park, Sung Yul
    YONSEI MEDICAL JOURNAL, 2015, 56 (06) : 1492 - 1496